Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Rakhi Kumar is Chief Accounting Officer at Roivant Sciences. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 19, 2025, each linked to the official Form 4.
Chief Accounting Officer
Disclosures on record
1
Companies involved
1
Roivant SciencesROIV
Feb 13, 2025Sold~$2.37Mdisclosed Feb 19
DetailsOfficial recordAs of the latest filing on , Rakhi Kumar reported holding 163,264 shares of Roivant Sciences (ROIV), worth about $6.32M at the last close of $39 (Nov 18, 2026). Holdings are also on file at Neuropace (NPCE); together they are worth about $6.51M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Roivant Sciences ROIV | 163,264 | 163K direct | $39 | $6.32M | Feb 13, 2025 |
| Neuropace NPCE | 23,039 | 23K direct | $8 | $189K | Jun 19, 2026 |
Is this Rakhi Kumar’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Rakhi Kumar has no open-market purchase on record since 2022. Sales in each of the last 4 years.
Rakhi Kumar reported 0 open-market purchases and 25 sales since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $2.37M1×1 trade |
| 2024 | — | $2.97M1×1 trade |
| 2023 | — | $4.36M12×12 trades |
| 2022 |
$157K11×11 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Feb 13, 2025, Rakhi Kumar reported holding 163,264 shares of Roivant Sciences (ROIV). At the last close of $39 on Nov 18, 2026, that is about $6.32M. This is the stake disclosed in filings, not a net worth.
No public filing gives Rakhi Kumar's net worth. What SEC Form 4 shows is the stock stake: 163,264 shares of Roivant Sciences (ROIV), about $6.32M at the last close, plus holdings in 1 other company, about $6.51M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Rakhi Kumar has no open-market purchase on record since 2022. Sales in each of the last 4 years.
In SEC filings since 2022: no open-market purchase is on record; the latest open-market sale is from 2025.
Roivant Sciences (ROIV), from 2022 to 2025: 0 purchases and 25 sales.
Rakhi Kumar reported 0 open-market purchases and 25 sales here, 2022 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.